Clinical Research Directory
Browse clinical research sites, groups, and studies.
Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor: He Huang
Summary
This study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but lack suitable donors. This project plans to use highly mismatched unrelated HLA mismatched donors. Ultimately, an unrelated human leukocyte antigen (HLA) mismatched allo HSCT transplantation plan will be established to improve the disease prognosis of this group of patients and truly enter the era of "everyone has a donor" for allo HSCT.
Official title: A Prospective Single-arm Trial on Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
29
Start Date
2022-08-04
Completion Date
2027-10-31
Last Updated
2025-02-05
Healthy Volunteers
No
Conditions
Interventions
Busulfan (Busulfex)
Myeloablative conditioning: Busulfan (Bu,3.2 mg/kg/d IV -8d \~-6d); Reduced intensity conditioning: Busulfan (Bu,3.2 mg/kg/d IV -7d\~-5d);
Cyclophosphamide (CTX)
Myeloablative conditioning: Cyclophosphamide (Cy,1.8g/m2, -5d, -4d) Cyclophosphamide is not used for reduced intensity conditioning
Fludarabine (Fludara)
Myeloablative conditioning: Fludarabine (Flu,30 mg/m2/d IV -6d \~ -2d); Reduced intensity conditioning: Fludarabine (Flu,30mg/m2 /d IV -10d\~-5d);
Semustine (MeccNU)
For both myeloablative and reduced intensity conditioning: Semustine (MeCCNU: 250 mg/m2 orally-3d)
Locations (1)
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China